Brooklyn ImmunoTherapeutics Inc News - BTX

Current Report Filing (8-k)

false000074859200007485922022-05-092022-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

false000074859200007485922022-05-242022-05-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

TABLE OF CONTENTSFiled pursuant to Rule 424(b)(3)Registration No. 333-264585PROSPECTUSBrooklyn ImmunoTherapeutics, Inc.13,714,284 Shares of...

Securities Registration Statement (simplified Form) (s-3)

TABLE OF CONTENTSAs filed with the Securities and Exchange Commission on April 29, 2022Registration No. 333- UNITED...

Proxy Statement (definitive) (def 14a)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14A INFORMATIONProxy Statement Pursuant to...

Current Report Filing (8-k)

false000074859200007485922022-04-152022-04-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

false000074859200007485922022-04-152022-04-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Annual Report (10-k)

false12-312021FY00007485920.50.52018 2019 2020 2021P5Y6M68800007485922021-01-012021-12-3100007485922021-06-30000...

Notification That Annual Report Will Be Submitted Late (nt 10-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File...

Current Report Filing (8-k)

false000074859200007485922022-03-062022-03-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act...

Current Report Filing (8-k)

false000074859200007485922022-01-182022-01-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Current Report Filing (8-k)

false000074859200007485922022-01-142022-01-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

false000074859200007485922021-12-162021-12-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:November 26,

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BTX News

Current Report Filing (8-k)

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Securities Registration Statement (simplified Form) (s-3)

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Annual Report (10-k)

Notification That Annual Report Will Be Submitted Late (nt 10-k)

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

Notice of Effectiveness (effect)

BTX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX) News

Brooklyn ImmunoTherapeutics Inc (BTX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BTX News

Current Report Filing (8-k)

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Securities Registration Statement (simplified Form) (s-3)

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Annual Report (10-k)

Notification That Annual Report Will Be Submitted Late (nt 10-k)

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

Notice of Effectiveness (effect)

BTX Discussion

Your Recent History